Enbrel Access is Plummeting

Market share is going down fast and it isn't because we can't sell. They are not contracting well and we keep losing plans left and right. It's sad for everyone who worked hard to make Enbrel the great product it once was.

Patients and plans prefer a pill to an injection. The only thing going for us was years of experience and contracting, and it is gone. The newest contracts just give discounts to keep Enbrel on plan formularies.

Less and less rhems considering Enbrel each day. Really a shame. Biosimilars are only going to make it harder if docs have to remember more competing brands.

 

The cash cow is bleeding a lot worse than is being reported.

 

Humira has maintained strong volume growth since the launch of Xeljanz, Otezla and Cosentyx, with the primary contraction in market share coming from Enbrel.

 

I don't sell in this arena, but for what its worth Enbrel essentially changed the lives of our family; sibling diagnosed with severe RA at age 13, and 2 years later she is playing sports and thriving.

Enbrel not only saved her life, but the lives of our family.

 

No question it's a great drug. The question is whether Amgen's national accounts team do anything other than shove their thumbs up their ass.

 

Michael Jordan was a great basketball player...but he's old and no longer playing. Enbrel should have been generic years ago.

 

It isn't just national accounts. There is so much discounting in this TA for both national and regional payers that Amjevita won't be worth anything by the time it is launched.

Newly diagnosed patients are getting pills after methotrexate, not biologics. Reimbursement actually use to help docs feel comfortable prescribing Enbrel rather than the newer brands.

Enbrel will be down in sales 15 - 25% since last year for the second quarter in a row with no good explanation, while Humira is growing at that rate. Indication based contracting will only make this worse in the coming year.

 

The home office folks need to get it together. How are we supposed to compete? Nobody seems to have an answer. New ways to decrease Enbrel scripts almost daily. The docs are blaming it on insurance coverage! It is getting worse by the day.

 

Nobody has been able to plug the hole. Management has doubts the product can turn around.

 

Who is the Ph.D Ex-Mckinsey Chinese marketing lead with no field experience? So he is in this role because McKinsey is on his resume, a minority, and has a fancy graduate degree but no experience.

 

Great job sinking the inflammation market. By the time biosimilars come out 60% discounts on list prices will be the norm. Medicaid is already getting Enbrel for free.

Good luck

 

Payers can't wait to cover Erelzi. That's all they talk about.

Sandoz will fix Amgen's mistakes. Your patents are filled with holes.

 

http://www.erelzi.com/globalassets/erelzi/erelzipi.pdf

The Amgen patent won't likely hold up until 2029. That's 3 potential presidential admins that will make biosimilars more prevalent.

 

Oh that guy, isn't his name Long Duc Dong?

 

Looking through the amgen directory and matching LinkedIn profiles, seems like it may be a guy with the initials JC.

 

You are thinking of Wae Tue Wong

 

The best part of the Enbrel's new overall strategy is the number of former CV failures who worked on it now both in the HQ and in the field. How were they hired on to Enbrel when access for CV products is lacking so badly?

We need leadership changes. We need winners.

 

Looks like another McKinsey consulting flameout who thinks he's hot shit and is going to save Enbrel. If he fails, which he will, the blame will be on us.

 

How do we have executives like JO publicly talking about free markets for drug pricing, and then hire a communist?

Kind of like being "the most innovative company" and then "being a biosimilar leader".

Relax on the coolaid guys.

 

Compliance is monitoring someone who is sharing contracting data with competitors. HR is monitoring this page and deleting everything it could before shutdown.